Emergence of the erythropoietin/erythropoietin receptor system as a novel cardiovascular therapeutic target

Journal of Cardiovascular Pharmacology

Volumn 58, Issue 6, 2011, Pages 570-574

  Satoh, Kimio ^a   Fukumoto, Yoshihiro ^a   Nakano, Makoto ^a   Kagaya, Yutaka ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

angiogenesis; erythropoietin; vascular remodeling

Indexed keywords

CYCLOPHILIN A; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CARDIOVASCULAR DISEASE; DRUG TARGETING; ENDOTHELIUM CELL; HOMEOSTASIS; HUMAN; HYPOXIA; ISCHEMIA; LUNG BLOOD VESSEL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; VASCULAR DISEASE;

ANIMALS; ANOXIA; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; HOMEOSTASIS; HUMANS; MICE; MICE, KNOCKOUT; MYOCARDIAL ISCHEMIA; RECEPTORS, ERYTHROPOIETIN;

EID: 83155175243     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318235e7bb     Document Type: Article

References (67)

1. Vanhoutte PM. Endothelial dysfunction: The first step toward coronary arteriosclerosis. Circ J. 2009;73:595-601.
2. Shimokawa H. Primary endothelial dysfunction: Atherosclerosis. J Mol Cell Cardiol. 1999;31:23-37. (Pubitemid 29078216)
3. Suzuki N, Ohneda O, Takahashi S, et al. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood. 2002;100:2279-2288.
4. Tada H, Kagaya Y, Takeda M, et al. Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion. Cardiovasc Res. 2006;71:466-477. (Pubitemid 44107864)
5. Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005;45:1406-1412. (Pubitemid 40615610)
6. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003;102:1340-1346. (Pubitemid 36988041)
7. Semenza GL. O2-regulated gene expression: Transcriptional control of cardiorespiratory physiology by HIF-1. J Appl Physiol. 2004;96: 1173-1177; discussion 1170-1172.
8. Petit RD, Warburton RR, Ou LC, et al. Exogenous erythropoietin fails to augment hypoxic pulmonary hypertension in rats. Respir Physiol. 1993; 91:271-282. (Pubitemid 23083407)
9. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ. 2004;11(suppl 1):S37-S44.
10. Noguchi CT, Wang L, Rogers HM, et al. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med. 2008;10:e36.
11. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967. (Pubitemid 27087709)
12. Voelkel NF, Tuder RM. Hypoxia-induced pulmonary vascular remodeling: A model for what human disease? J Clin Invest. 2000;106:733-738.
13. Steudel W, Scherrer-Crosbie M, Bloch KD, et al. Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3. J Clin Invest. 1998;101:2468-2477. (Pubitemid 28270441)
14. Satoh K, Kagaya Y, Nakano M, et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation. 2006; 113:1442-1450. (Pubitemid 43739441)
15. Beleslin-Cokic BB, Cokic VP, Yu X, et al. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood. 2004;104:2073-2080. (Pubitemid 39297859)
16. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A. 1994; 91:3974-3978. (Pubitemid 24139555)
17. Nakano M, Satoh K, Fukumoto Y, et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res. 2007;100:662-669. (Pubitemid 46594880)
18. Nishihara M, Miura T, Miki T, et al. Modulation of the mitochondrial permeability transition pore complex in GSK-3 beta-mediated myocardial protection. J Mol Cell Cardiol. 2007;43:564-570. (Pubitemid 47615050)
19. Vannucchi AM, Grossi A, Bosi A, et al. Effects of cyclosporin A on erythropoietin production by the human Hep3B hepatoma cell line. Blood. 1993;82:978-984. (Pubitemid 23221684)
20. Handschumacher RE, Harding MW, Rice J, et al. Cyclophilin: A specific cytosolic binding protein for cyclosporin a. Science. 1984;226:544-547. (Pubitemid 14018525)
21. Harding MW, Handschumacher RE, Speicher DW. Isolation and amino acid sequence of cyclophilin. J Biol Chem. 1986;261:8547-8555. (Pubitemid 17202738)
22. Siekierka JJ, Hung SH, Poe M, et al. A cytosolic binding protein for the immunosuppressant fk506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature. 1989;341:755-757. (Pubitemid 19260892)
23. Bierer BE. Cyclosporin a, fk506, and rapamycin: Binding to immunophilins and biological action. Chem Immunol. 1994;59:128-155. (Pubitemid 24273963)
24. Choi KJ, Piao YJ, Lim MJ, et al. Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatin-induced cell death. Cancer Res. 2007;67:3654-3662.
25. Marks AR. Cellular functions of immunophilins. Physiol Rev. 1996;76: 631-649. (Pubitemid 26286074)
26. Galat A, Metcalfe SM. Peptidylproline cis/trans isomerases. Prog BiophysMol Biol. 1995;63:67-118.
27. Zhu C, Wang X, Deinum J, et al. Cyclophilin A participates in the nuclear translocation of apoptosis-inducing factor in neurons after cerebral hypoxia-ischemia. J Exp Med. 2007;204:1741-1748. (Pubitemid 47236312)
28. Krummrei U, Bang R, Schmidtchen R, et al. Cyclophilin-a is a zincdependent DNA binding protein in macrophages. FEBS Lett. 1995;371: 47-51.
29. Baines CP, Kaiser RA, Purcell NH, et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature. 2005;434:658-662. (Pubitemid 40488559)
30. Du H, Guo L, Fang F, et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimers disease. Nat Med. 2008;14:1097-1105.
31. Alexander RW. Theodore cooper memorial lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: A new perspective. Hypertension. 1995; 25:155-161.
32. Omar HA, Cherry PD, Mortelliti MP, et al. Inhibition of coronary artery superoxide dismutase attenuates endothelium-dependent and -independent nitrovasodilator relaxation. Circ Res. 1991;69:601-608.
33. Baas AS, Berk BC. Differential activation of mitogen-activated protein kinases by h2o2 and o2- in vascular smooth muscle cells. Circ Res. 1995; 77:29-36.
34. Matoba T, Shimokawa H, Nakashima M, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest. 2000; 106:1521-1530. (Pubitemid 32040953)
35. Takaki A, Morikawa K, Tsutsui M, et al. Crucial role of nitric oxide synthases system in endothelium-dependent hyperpolarization in mice. J Exp Med. 2008;205:2053-2063.
36. Clempus RE, Griendling KK. Reactive oxygen species signaling in vascular smooth muscle cells. Cardiovasc Res. 2006;71:216-225.
37. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin ii stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148. (Pubitemid 24176909)
38. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res. 1992;70:593-599.
39. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999; 138:S419-S420. (Pubitemid 29523224)
40. Libby P, Okamoto Y, Rocha VZ, et al. Inflammation in atherosclerosis: Transition from theory to practice. Circ J. 74:213-220.
41. Inoue T, Node K. Molecular basis of restenosis and novel issues of drugeluting stents. Circ J. 2009;73:615-621.
42. Jin ZG, Lungu AO, Xie L, et al. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24:1186-1191. (Pubitemid 38880006)
43. Kim H, Kim WJ, Jeon ST, et al. Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages. Clin Immunol. 2005;116:217-224. (Pubitemid 41112725)
44. 4+ t cells by extracellular cyclophilin A. J Leukoc Biol. 2007;82:613-618. (Pubitemid 47367153)
45. Yang Y, Lu N, Zhou J, et al. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxford). 2008;47: 1299-1310.
46. Satoh K, Matoba T, Suzuki J, et al. Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation. 2008;117:3088-3098.
47. Kunieda T, Minamino T, Nishi J, et al. Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. Circulation. 2006; 114:953-960. (Pubitemid 44337139)
48. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: Animal and human studies. Circulation. 2003;108: 2034-2040. (Pubitemid 37337574)
49. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003;42:1075-1081. (Pubitemid 37549058)
50. Bruemmer D, Collins AR, Noh G, et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin- deficientmice. J Clin Invest. 2003;112:1318-1331. (Pubitemid 38057686)
51. Yoshimura K, Aoki H, Ikeda Y, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med. 2005;11: 1330-1338. (Pubitemid 41752914)
52. Sun J, Sukhova GK, Yang M, et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest. 2007;117:3359-3368. (Pubitemid 350096992)
53. Satoh K, Nigro P, Matoba T, et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med. 2009;15:649-656.
54. Satoh K, Shimokawa H, Berk BC. Cyclophilin A: Promising new target in cardiovascular therapy. Circ J. 2010;74:2249-2256.
55. Thomas M, Gavrila D, McCormick ML, et al. Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation. 2006;114:404-413. (Pubitemid 44264822)
56. Higashi Y, Noma K, Yoshizumi M, et al. Endothelial function and oxidative stress in cardiovascular diseases. Circ J. 2009;73:411-418.
57. Nigro P, Abe J, Woo CH, et al. Pkczeta decreases ENOS protein stability via inhibitory phosphorylation of erk5. Blood. 2010;116:1971-1979.
58. Morikawa K, Shimokawa H, Matoba T, et al. Pivotal role of cu, zn-superoxide dismutase in endothelium-dependent hyperpolarization. J Clin Invest. 2003;112:1871-1879. (Pubitemid 38063710)
59. Maseri A, Beltrame JF, Shimokawa H. Role of coronary vasoconstriction in ischemic heart disease and search for novel therapeutic targets. Circ J. 2009;73:394-403.
60. Nigro P, Satoh K, ODell MR, et al. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 2011;208:53-66.
61. Satoh K, Berk BC, Shimokawa H. Vascular-derived reactive oxygen species for homeostasis and diseases. Nitric Oxide. 2011;25:211-215.
62. Satoh K, Nigro P, Zeidan A, et al. Cyclophilin A promotes cardiac hypertrophy in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol. 2011;31:1116-1123.
63. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: Important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2011;301:H287-H296.
64. Abe K, Shimokawa H, Morikawa K, et al. Long-term treatment with a rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res. 2004;94:385-393. (Pubitemid 38240731)
65. Itoh T, Nagaya N, Murakami S, et al. C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004;170:1204-1211. (Pubitemid 39577379)
66. Champion HC, Bivalacqua TJ, DSouza FM, et al. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses. Circ Res. 1999;84:1422-1432. (Pubitemid 29293221)
67. Satoh K, Nigro P, Berk BC. Oxidative stress and vascular smooth muscle cell growth: A mechanistic linkage by cyclophilin A. Antioxid Redox Signal. 2010;12:675-682.